Applications for open access normalized synthesis in metastatic prostate cancer trials

Recent metastatic castration-resistant prostate cancer (mCRPC) clinical trials have integrated homologous recombination and DNA repair deficiency (HRD/DRD) biomarkers into eligibility criteria and secondary objectives. These trials led to the approval of some PARP inhibitors for mCRPC with HRD/DRD i...

Descripción completa

Detalles Bibliográficos
Autores principales: Luechtefeld, Thomas, Bozada, Thomas, Goel, Rahul, Wang, Lin, Paller, Channing J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Artificial Intelligence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511148/
https://www.ncbi.nlm.nih.gov/pubmed/36171797
http://dx.doi.org/10.3389/frai.2022.984836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511148/
https://www.ncbi.nlm.nih.gov/pubmed/36171797
http://dx.doi.org/10.3389/frai.2022.984836

Ejemplares similares